Inactive Instrument

Provectus Biopharmaceuticals Inc Stock price Nyse

Equities

US74373P1084

Biotechnology & Medical Research

End-of-day quote Nyse
- USD 0.00% Intraday chart for Provectus Biopharmaceuticals Inc
Sales 2021 - Sales 2022 0.99 Capitalization 45.43M
Net income 2021 -5M Net income 2022 -3M EV / Sales 2021 -
Net Debt 2021 1.06M Net Debt 2022 2.16M EV / Sales 2022 48,121,944 x
P/E ratio 2021
-4.05 x
P/E ratio 2022
-12.8 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 90.58%
More Fundamentals * Assessed data
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022 CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Provectus Biopharmaceuticals Inc. Establishes Research Collaboration with University of Texas Medical Branch At Galveston CI
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections CI
Provectus Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair CI
Provectus Biopharmaceuticals Presents Data from PV-10 Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology Congress CI
More news
Managers TitleAgeSince
Chief Executive Officer 55 17-04-02
Founder 61 01-12-31
Director of Finance/CFO 58 17-07-31
Members of the board TitleAgeSince
Founder 61 01-12-31
Director/Board Member 76 18-04-26
Chief Executive Officer 55 17-04-02
More insiders
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company's lead molecule is named rose bengal sodium (RBS). The Company's small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company's HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
More about the company
  1. Stock
  2. Equities
  3. Stock Provectus Biopharmaceuticals, Inc.
  4. Stock Provectus Biopharmaceuticals Inc - Nyse